Glucagon-Like Peptide-1 Analogues and Anxiety and Abnormal Eating Behaviours in Type 2 Diabetes: A Case ReportAnne Marie Doherty1*, Rosarie Atkinson2 and Mark Chamley3
- *Corresponding Author:
- Anne Marie Doherty
Diabetes Department, King’s College Hospital
London, SE5 9RS, United Kingdom
Tel: +44 (0)203 299 1350
Fax: +44 (0)203 299 1350
E-mail: [email protected]
Received date: May 05, 2014; Accepted date: May 29, 2014; Published date: June 04, 2014
Citation: Doherty AM, Atkinson R, Chamley M (2014) Glucagon-Like Peptide-1 Analogues and Anxiety and Abnormal Eating Behaviours in Type 2 Diabetes: A Case Report. J Diabetes Metab 5:381. doi: 10.4172/2155-6156.1000381
Copyright: © 2014 Doherty AM et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Psychological and psychiatric problems are common in diabetes. Glucagon-like peptide-1 (GLP-1) analogues are effective in the management of type 2 diabetes as second or third-line treatment, and are thought to have a central effect on appetite regulation. There is little evidence regarding the effect of GLP-1 analogues on anxiety. This is a case report of a patient with type 2 diabetes, obesity, anxiety and disordered eating who was commenced on Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue. This patient reported, in addition to improved glycaemic control, a marked improvement in the anxiety which had been present all her life, and had driven her binge eating. This anxiety had persisted despite anxiolytic medications and cognitive behaviour therapy. Any medication which could have a positive effect on anxiety and diabetes both would be valuable. Glucagon like peptide analogues may have a role in the management of co-morbid anxiety and type 2 diabetes. Further research is required into this area.